WallStSmart

Harrow Health Inc (HROW)vsTakeda Pharmaceutical Co Ltd ADR (TAK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Takeda Pharmaceutical Co Ltd ADR generates 1676915% more annual revenue ($4.51T vs $268.68M). TAK leads profitability with a 4.3% profit margin vs -5.6%. TAK earns a higher WallStSmart Score of 57/100 (C).

HROW

Avoid

17

out of 100

Grade: F

Growth: 4.7Profit: 3.0Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: 0.89

TAK

Buy

57

out of 100

Grade: C

Growth: 6.7Profit: 4.0Value: 6.3Quality: 5.0
Piotroski: 4/9Altman Z: 1.18

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HROW0 strengths · Avg: 0/10

No standout strengths identified

TAK4 strengths · Avg: 9.8/10
PEG RatioValuation
0.4010/10

Growing faster than its price suggests

Price/BookValuation
1.0x10/10

Reasonable price relative to book value

EPS GrowthGrowth
330.2%10/10

Earnings expanding 330.2% YoY

Market CapQuality
$51.34B9/10

Large-cap with strong market position

Areas to Watch

HROW4 concerns · Avg: 2.3/10
Market CapQuality
$1.31B3/10

Smaller company, higher risk/reward

Price/BookValuation
45.1x2/10

Trading at 45.1x book value

Return on EquityProfitability
-35.4%2/10

ROE of -35.4% — below average capital efficiency

Revenue GrowthGrowth
-7.6%2/10

Revenue declined 7.6%

TAK4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
3.9%4/10

3.9% revenue growth

Return on EquityProfitability
2.5%3/10

ROE of 2.5% — below average capital efficiency

Profit MarginProfitability
4.3%3/10

4.3% margin — thin

Operating MarginProfitability
3.1%3/10

Operating margin of 3.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : HROW

HROW has a balanced fundamental profile.

Bull Case : TAK

The strongest argument for TAK centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.40 suggests the stock is reasonably priced for its growth.

Bear Case : HROW

The primary concerns for HROW are Market Cap, Price/Book, Return on Equity. Debt-to-equity of 10.47 is elevated, increasing financial risk.

Bear Case : TAK

The primary concerns for TAK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 42.8x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.

Key Dynamics to Monitor

HROW profiles as a turnaround stock while TAK is a value play — different risk/reward profiles.

HROW carries more volatility with a beta of 0.34 — expect wider price swings.

TAK is growing revenue faster at 3.9% — sustainability is the question.

HROW generates stronger free cash flow (-9M), providing more financial flexibility.

Bottom Line

TAK scores higher overall (57/100 vs 17/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Harrow Health Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Harrow Health, Inc. is an ophthalmology-focused healthcare company. The company is headquartered in San Diego, California.

Takeda Pharmaceutical Co Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.

Want to dig deeper into these stocks?